APA (7th ed.) Citation

Petersen, K. L., Iyengar, S., Chappell, A. S., Lobo, E. D., Reda, H., Prucka, W. R., & Verfaille, S. J. (2014). Safety, tolerability, pharmacokinetics, and effects on human experimental pain of the selective ionotropic glutamate receptor 5 (iGluR5) antagonist LY545694 in healthy volunteers. Pain (Amsterdam), 155(5), 929-936. https://doi.org/10.1016/j.pain.2014.01.019

Chicago Style (17th ed.) Citation

Petersen, Karin L., Smriti Iyengar, Amy S. Chappell, Evelyn D. Lobo, Haatem Reda, William R. Prucka, and Steven J. Verfaille. "Safety, Tolerability, Pharmacokinetics, and Effects on Human Experimental Pain of the Selective Ionotropic Glutamate Receptor 5 (iGluR5) Antagonist LY545694 in Healthy Volunteers." Pain (Amsterdam) 155, no. 5 (2014): 929-936. https://doi.org/10.1016/j.pain.2014.01.019.

MLA (9th ed.) Citation

Petersen, Karin L., et al. "Safety, Tolerability, Pharmacokinetics, and Effects on Human Experimental Pain of the Selective Ionotropic Glutamate Receptor 5 (iGluR5) Antagonist LY545694 in Healthy Volunteers." Pain (Amsterdam), vol. 155, no. 5, 2014, pp. 929-936, https://doi.org/10.1016/j.pain.2014.01.019.